Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Net Income

Bottom-line profit after all expenses, interest, and taxes.

Stevanato Group S.p.A.NYSE: STVN

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of €23M fell 22.6% year over year, behind the -0.2% change in trailing-twelve-month net income. Sequentially, it fell 17.9% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.

Context

  • Net income amounted to 11.8% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of €149.98M (+11.7%) for the fiscal year ending Dec 2026, a slowdown from the +14.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€23M-17.9% QoQ
Last fiscal yearDec 2025
€134.28M+14.0% YoY
LTMJun 2026
€134.25M-0.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.6%+20.3%+42.9 pp
1 year+14.0%+11.7%-2.3 pp
3-year CAGR-2.0%+11.6%+13.6 pp
5-year CAGR+20.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the income statement

Latest · FY2025
134.28M EUR
Year-over-year change
+14.0%
4-year CAGR
-0.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.2% is the 6th highest of 11, against a peer median of +8.5%.
  • Net income amounts to 11.0% of revenue for STVN, versus a peer median of 9.2%.
STVN Competitors
Net Income for STVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATRAptarGroup, Inc.LTM Jun 2026$362.52M USD-7.4%+18.0%9.2%
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$338.34M USD+161.1%—2.2%
CHEChemed CorporationLTM Jun 2026$274.99M USD-5.3%+2.0%10.6%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$160.12M USD+35.2%+19.9%9.9%
STVNStevanato Group S.p.A.LTM Jun 2026€134.25M EUR-0.2%-2.0%11.0%
MASIMasimo CorporationLTM Apr 2026$76.3M USD+115.4%—4.9%
BLCOBausch + Lomb CorporationLTM Jun 2026-$171M USD+37.4%—3.2%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026-$191.64M USD+22.4%—24.7%
NUVLNuvalent, Inc.LTM Mar 2026-$450.07M USD-49.6%——
AVTRAvantor, Inc.LTM Jun 2026-$578M USD-184.1%—8.8%
TFXTeleflex IncorporatedLTM Jun 2026-$1.03B USD-636.3%—39.6%
Peer median (excluding STVN) —+8.5%+18.0%9.2%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue843.92M983.68M1.09B1.1B1.14B
Cost of Revenue578.52M663.88M745.46M801.72M809.15M
Gross Profit265.41M319.8M339.89M302.32M330.33M
Gross Margin31.4%32.5%31.3%27.4%29.0%
Research & Development29.62M34.39M35.67M31.67M24.4M
Selling, General & Admin82.95M111.83M113.92M118.6M122.85M
Operating Expenses103.18M127.37M139.17M141.18M147.25M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
EBITDA226.93M256.4M272.35M247.8M292.01M
EBITDA Margin26.9%26.1%25.1%22.4%25.6%
Operating Income162.23M192.43M200.72M161.14M183.08M
Operating Margin19.2%19.6%18.5%14.6%16.1%
Interest Income548K648K792K1.72M12.49M
Interest Expense4.87M3.94M4.32M6.86M21.8M
Other Income / Expenses3.45M(4.79M)(11.17M)(854K)(1.44M)
Income Before Tax165.67M187.64M189.55M160.29M181.64M
Pre-Tax Margin19.6%19.1%17.5%14.5%15.9%
Income Tax Expense31.4M44.63M43.86M42.52M47.35M
Net Income134.32M142.85M145.63M117.78M134.28M
Net Margin15.9%14.5%13.4%10.7%11.8%
EPS (Basic)0.530.530.550.430.49
EPS (Diluted)0.530.530.550.430.49
Weighted Avg Shares264.7M264.7M264.95M272.87M273M
Weighted Avg Shares (Diluted)264.7M264.7M264.98M272.88M273M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.